CanBas Co. Ltd. | Balance Sheet

Fiscal year is July-June. All values JPY Thousands.
2014
2015
2016
2017
2018
Cash & Short Term Investments
323,354.00
885,355.00
815,110.00
889,368.00
466,277.00
Total Accounts Receivable
12,380.00
60,603.00
77,709.00
71,313.00
66,529.00
Inventories
951.00
1,027.00
1,341.00
1,030.00
643.00
Other Current Assets
6,493.00
6,112.00
29,268.00
11,842.00
13,018.00
Total Current Assets
343,178.00
953,097.00
923,428.00
973,558.00
546,469.00
Net Property, Plant & Equipment
31,411.00
23,449.00
23,025.00
-
-
Total Investments and Advances
20,694.00
-
-
-
-
Intangible Assets
1,333.00
1,023.00
730.00
220.00
-
Other Assets
864.00
20,290.00
20,090.00
19,503.00
31,819.00
Total Assets
397,480.00
997,859.00
967,273.00
993,281.00
578,289.00
Income Tax Payable
8,313.00
10,140.00
11,954.00
20,882.00
20,431.00
Other Current Liabilities
17,854.00
22,944.00
26,181.00
45,305.00
135,921.00
Total Current Liabilities
26,167.00
33,084.00
38,135.00
66,187.00
156,352.00
Long-Term Debt
36,645.00
-
-
-
-
Total Liabilities
62,812.00
33,084.00
38,135.00
66,187.00
156,352.00
Common Equity (Total)
334,668.00
964,775.00
929,138.00
927,094.00
421,936.00
Total Shareholders' Equity
334,668.00
964,775.00
929,138.00
927,094.00
421,936.00
Total Equity
334,668.00
964,775.00
929,138.00
927,094.00
421,936.00
Liabilities & Shareholders' Equity
397,480.00
997,859.00
967,273.00
993,281.00
578,289.00

About CanBas Co.

View Profile
Address
2-2-1 Otemachi
Numazu Shizuoka 410
Japan
Employees -
Website http://www.canbas.co.jp
Updated 07/08/2019
CanBas Co., Ltd. engages in pharmaceutical business. It focuses on the research and development of anti-cancer agent, drugs, and technologies which has minor impact on normal cell. Its technologies include drugs for the G2 check point and a screening system to find selective abrogates of the G2 check point.